litlas
Log inCreate account

Jan A. Burger

Active 1999–2025

189
Papers
33,707
Citations
102
h-index
185
i10-index

Citations

Citations per year for Jan A. Burger1992: 2 citations2000: 8 citations2001: 29 citations2002: 45 citations2003: 60 citations2004: 52 citations2005: 70 citations2006: 78 citations2007: 114 citations2008: 135 citations2009: 168 citations2010: 173 citations2011: 183 citations2012: 223 citations2013: 326 citations2014: 301 citations2015: 470 citations2016: 369 citations2017: 391 citations2018: 402 citations2019: 1,376 citations2020: 1,594 citations2021: 1,620 citations2022: 1,011 citations2023: 723 citations2024: 1,121 citations2025: 454 citations2026: 16 citations1993–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,018 citing papers, 27.9% of this breakdownChina: 951 citing papers, 8.8% of this breakdownGermany: 788 citing papers, 7.3% of this breakdownItaly: 728 citing papers, 6.7% of this breakdownUnited Kingdom: 692 citing papers, 6.4% of this breakdownFrance: 443 citing papers, 4.1% of this breakdownSpain: 335 citing papers, 3.1% of this breakdownAustralia: 332 citing papers, 3.1% of this breakdownCanada: 279 citing papers, 2.6% of this breakdownNetherlands: 258 citing papers, 2.4% of this breakdownSwitzerland: 225 citing papers, 2.1% of this breakdownJapan: 221 citing papers, 2% of this breakdown
0%27.9%Other 23.5%

Institutions

Fields

  • Medicine75.8%
  • Biochemistry, Genetics and Molecular Biology14.6%
  • Immunology and Microbiology6.6%
  • Chemistry0.7%
  • Computer Science0.4%
  • Neuroscience0.4%
  • Other1.5%

Topics

  • Chronic Lymphocytic Leukemia Research12.3%
  • Lymphoma Diagnosis and Treatment7.6%
  • Chronic Myeloid Leukemia Treatments4.7%
  • Acute Myeloid Leukemia Research4.2%
  • Immunodeficiency and Autoimmune Disorders3.1%
  • Chemokine receptors and signaling3.1%
  • Other65%

Coauthors

All papers

Open in search
  1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  2. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    Authors: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 cited by 269

  3. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 cited by 2,249

  4. Targeting B cell receptor signalling in cancer: preclinical and clinical advances

    Authors: Jan A. Burger, Adrian Wiestner - Nature reviews. Cancer 2018 cited by 422

  5. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Authors: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 cited by 473

  6. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

    Authors: Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C. Issa, Guillermo Montalban‐Bravo, Nicholas J. Short, Musa Yılmaz, Prithviraj Bose, Elias Jabbour, Koichi Takahashi, Jan A. Burger, Guillermo Garcia‐Manero, Nitin Jain, Steven M. Kornblau, Philip A. Thompson, Zeev Estrov, Lucia Masárová, Koji Sasaki, Srđan Verstovšek, Alessandra Ferrajoli, William Weirda, Sa A. Wang, Sergej Konoplev, Zhining Chen, Sherry Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S. Welch, Hagop M. Kantarjian, Marina Konopleva - The Lancet Haematology 2020 cited by 331

  7. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    Authors: Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Nathan Fowler, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yılmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Koji Sasaki, Rashmi Kanagal‐Shamanna, Keyur P. Patel, Jeffrey L. Jorgensen, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda - New England Journal of Medicine 2019 cited by 504

  8. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Authors: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 cited by 463

  9. Bruton Tyrosine Kinase Inhibitors

    Authors: Jan A. Burger - The Cancer Journal 2019 cited by 193

  10. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia

    Authors: Wan Zhang, Dunyaporn Trachootham, Jinyun Liu, Gang Chen, Hélène Pelicano, Celia Garcı́a-Prieto, Weiqin Lu, Jan A. Burger, Carlo M. Croce, William Plunkett, Michael J. Keating, Peng Huang - Nature Cell Biology 2012 cited by 353

  11. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    Authors: Binyamin A. Knisbacher, Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylor‐Weiner, Pablo Bousquets‐Muñoz, Ander Díaz‐Navarro, Andrew Dunford, Shankara Anand, Helene Kretzmer, Jesús Gutiérrez‐Abril, Sara López-Tamargo, Stacey M. Fernandes, Clare Sun, Mariela Sivina, Laura Z. Rassenti, Christof Schneider, Shuqiang Li, Laxmi Parida, Alexander Meissner, François Aguet, Jan A. Burger, Adrian Wiestner, Thomas J. Kipps, Jennifer R. Brown, Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 cited by 148

  12. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

    Authors: Jan A. Burger, Thomas J. Kipps - Blood 2005 cited by 1,165

  13. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

    Authors: Constantine S. Tam, Judith Trotman, Stephen Opat, Jan A. Burger, Gavin Cull, David Gottlieb, Rosemary Harrup, Patrick B. Johnston, Paula Marlton, Javier Muñoz, John F. Seymour, David Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang, Andrew W. Roberts - Blood 2019 cited by 367

  14. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

    Authors: Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Koji Sasaki, Nathan Fowler, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yılmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Rashmi Kanagal‐Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A. Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda - JAMA Oncology 2021 cited by 112

  15. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien - Clinical Cancer Research 2020 cited by 183

  16. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    Authors: Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutré, Marie‐Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael M. Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger - Haematologica 2017 cited by 258

  17. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

    Authors: Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Joseph D. Khoury, Jeffrey L. Jorgensen, Yesid Alvarado, Marina Konopleva, Guillermo Garcia‐Manero, Tapan M. Kadia, Musa Yılmaz, Gautam Bortakhur, Jan A. Burger, Steven M. Kornblau, William G. Wierda, Courtney D. DiNardo, Alessandra Ferrajoli, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Elias Jabbour - The Lancet Oncology 2018 cited by 241

  18. B cell receptor signaling in chronic lymphocytic leukemia

    Authors: Jan A. Burger, Nicholas Chiorazzi - Trends in Immunology 2013 cited by 355

  19. Treatment of Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger - New England Journal of Medicine 2020 cited by 235

  20. Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

    Authors: Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Deborah Thomas, Rebecca Garris, Stefan Faderl, Jan A. Burger, Michael Rytting, Alessandra Ferrajoli, William G. Wierda, Srđan Verstovšek, Richard E. Champlin, Partow Kebriaei, Deborah McCue, Xuelin Huang, Elias Jabbour, Guillermo Garcia‐Manero, Zeev Estrov, Hagop M. Kantarjian - Cancer 2015 cited by 223

  21. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

    Authors: Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz - Blood 2017 cited by 253

  22. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

    Authors: Julia Hoellenriegel, Dirk Zboralski, Christian Maasch, Nathalie Y. Rosin, William G. Wierda, Michael J. Keating, Anna Kruschinski, Jan A. Burger - Blood 2013 cited by 236

  23. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

    Authors: Jan A. Burger, Dan A. Landau, Amaro Taylor‐Weiner, Ivana Božić, Huidan Zhang, Kristopher A. Sarosiek, Lili Wang, Chip Stewart, Jean Fan, Julia Hoellenriegel, Mariela Sivina, Adrian M. Dubuc, Cameron Fraser, Yulong Han, Shuqiang Li, Kenneth J. Livak, Lihua Zou, Youzhong Wan, Sergej Konoplev, Carrie Sougnez, Jennifer R. Brown, Lynne V. Abruzzo, Scott L. Carter, Michael J. Keating, Matthew S. Davids, William G. Wierda, Kristian Cibulskis, Thorsten Zenz, Lillian Werner, Paola Dal Cin, Peter Kharchencko, Donna Neuberg, Hagop M. Kantarjian, Eric S. Lander, Stacey Gabriel, Susan O’Brien, Anthony Letai, David A. Weitz, Martin A. Nowak, Gad Getz, Catherine J. Wu - Nature Communications 2016 cited by 346

  24. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 cited by 656